Alpha 2.0
Login Register
» Authors » Mark A Aldersley

Mark A Aldersley

Explore the profile of Mark A Aldersley including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 8
Citations 875
Followers 0
Related Specialties
Gastroenterology
General Medicine
General Surgery
Top 10 Co-Authors
Graham R Foster
Vattipally Sreenu
John McLauchlan
Paul Richardson
Andrew Ustianowski
William Rosenberg
Elihu Aranday-Cortes
Kosh Agarwal
Emma C Thomson
Douglas Macdonald
Published In
J Hepatol
Transplantation
Frontline Gastroenterol
Hepatology
Lancet
Affiliations
Soon will be listed here.
Recent Articles
1.
Real-world clinical effectiveness and sustainability of universal bloodborne virus testing in an urban emergency department in the UK
Smout E, Phyu K, Hughes G, Parker L, Rezai R, Evans A, et al.
Sci Rep . 2022 Nov; 12(1):19257. PMID: 36357472
Innovative testing approaches and care pathways are required to meet HIV, hepatitis B (HBV) and hepatitis C (HCV) elimination goals. Routine testing for blood-borne viruses (BBVs) within emergency departments (EDs)...
2.
Factors Associated With Outcomes of Patients With Primary Sclerosing Cholangitis and Development and Validation of a Risk Scoring System
Goode E, Clark A, Mells G, Srivastava B, Spiess K, Gelson W, et al.
Hepatology . 2018 Dec; 69(5):2120-2135. PMID: 30566748
We sought to identify factors that are predictive of liver transplantation or death in patients with primary sclerosing cholangitis (PSC), and to develop and validate a contemporaneous risk score for...
3.
Reply to: "Reply to: 'Response to DAA therapy in the NHS England Early Access Programme for rare HCV subtypes from low and middle income countries'"
da Silva Filipe A, Sreenu V, Hughes J, Aranday-Cortes E, Irving W, Foster G, et al.
J Hepatol . 2018 Jan; 68(4):864-866. PMID: 29339112
No abstract available.
4.
Response to DAA therapy in the NHS England Early Access Programme for rare HCV subtypes from low and middle income countries
da Silva Filipe A, Sreenu V, Hughes J, Aranday-Cortes E, Irving W, Foster G, et al.
J Hepatol . 2017 Aug; 67(6):1348-1350. PMID: 28789880
No abstract available.
5.
Patient understanding of liver cirrhosis and improvement using multimedia education
Goldsworthy M, Fateen W, Thygesen H, Aldersley M, Rowe I, Jones R
Frontline Gastroenterol . 2017 Jul; 8(3):214-219. PMID: 28706622
Objective: For patients to engage with the long-term management of liver cirrhosis, sufficient understanding of their condition is essential. The aim of this study was to assess baseline patient knowledge...
6.
Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
Armstrong M, Gaunt P, Aithal G, Barton D, Hull D, Parker R, et al.
Lancet . 2015 Nov; 387(10019):679-690. PMID: 26608256
Background: Glucagon-like peptide-1 (GLP-1) analogues reduce hepatic steatosis, concentrations of liver enzymes, and insulin resistance in murine models of fatty liver disease. These analogues are licensed for type 2 diabetes,...
7.
Liver toxicity associated with sofosbuvir, an NS5A inhibitor and ribavirin use
Dyson J, Hutchinson J, Harrison L, Rotimi O, Tiniakos D, Foster G, et al.
J Hepatol . 2015 Sep; 64(1):234-8. PMID: 26325535
Hepatitis C virus (HCV) infection is a major cause of end-stage liver disease and hepatocellular carcinoma. There have been rapid advances in HCV treatment with the development of oral direct-acting...
8.
Donor risk index and MELD interactions in predicting long-term graft survival: a single-centre experience
Bonney G, Aldersley M, Asthana S, Toogood G, Pollard S, Lodge J, et al.
Transplantation . 2009 Jun; 87(12):1858-63. PMID: 19543065
Introduction: Feng et al. described the donor risk index (DRI) in North American liver transplant recipients. We evaluated the effect of the DRI and model for end-stage liver disease (MELD)...